Wnt-7b serves as an important agonist of the Wnt/β-catenin signaling pathway [23,24], possibly preventing the phosphorylation and degradation of β-catenin induced by GSK-3β inhibition in cytoplasm; the accumulated β-catenin would translocate to the nucleus to bind with T-cell factor/lymphoid enhancer factor and then affect the expression of Wnt target genes, including cyclin D1 and c-Myc, eventually promoting tumor pathogenesis [25,26]. The gene discussed is GSK3B; the disease is neoplasm.